H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Kura Oncology (KURA – Research Report) today and set a price target of $40.00.
Joseph Pantginis has given his Buy rating due to a combination of factors including Kura Oncology’s strong financial position and strategic advancements in their drug development pipeline. The company reported a better-than-expected EPS for the first quarter of 2025 and holds a robust cash position, bolstered by a milestone payment from their partner, Kyowa Kirin. This financial stability is expected to support the company’s operations into 2027, facilitating the progress of their lead candidate, ziftomenib, towards commercialization.
Moreover, Kura Oncology’s recent submission of a New Drug Application for ziftomenib, targeting NPM1-m r/r AML, marks a significant milestone. The anticipation of a Priority Review acceptance and ongoing pre-commercial activities further strengthen the company’s prospects. Additionally, Kura is actively expanding ziftomenib’s potential into new indications and advancing other clinical-stage programs, positioning the company as a catalyst-driven entity with multiple upcoming data readouts and regulatory milestones.
According to TipRanks, Pantginis is an analyst with an average return of -19.8% and a 22.78% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and Actinium Pharmaceuticals.
In another report released today, Barclays also maintained a Buy rating on the stock with a $11.00 price target.